As the COVID-19 pandemic spreads nationwide and is gradually considered an endemic disease that could be treated at home, demand for medicine has increased sharply. Pharmaceutical enterprises is expected to benefit from the situation.
Social distancing and strict control at hospitals, and economic recession due to COVID-19 resulted in lower sales of both prescription and non-prescription drugs. However, many companies still witnessed outstanding performance.
Pharmaceutical stocks are experiencing an upsurge as fears of coronavirus have boosted demand for healthcare products and services, lifting demand for shares.